As HER2 was reportedly expressed in 30.3% of ESCC patients (Mimura et al, 2005), T-cell-based immunotherapy and monoclonal antibodies targeted against HER2 are therefore attractive approaches as a novel immunoadjuvant therapy for ESCC patients. The gene discussed is ERBB2; the disease is esophageal squamous cell carcinoma.